JP2003073315A - Anti-inflammatory vegetable ingredients - Google Patents

Anti-inflammatory vegetable ingredients

Info

Publication number
JP2003073315A
JP2003073315A JP2001267545A JP2001267545A JP2003073315A JP 2003073315 A JP2003073315 A JP 2003073315A JP 2001267545 A JP2001267545 A JP 2001267545A JP 2001267545 A JP2001267545 A JP 2001267545A JP 2003073315 A JP2003073315 A JP 2003073315A
Authority
JP
Japan
Prior art keywords
compound
bidens
inflammatory
extract
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001267545A
Other languages
Japanese (ja)
Other versions
JP4864252B2 (en
Inventor
Toru Okuyama
徹 奥山
Masaki Baba
正樹 馬場
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSASHINO MENEKI KENKYUSHO KK
Musashino Research Institute for Immunity Co Ltd
Original Assignee
MUSASHINO MENEKI KENKYUSHO KK
Musashino Research Institute for Immunity Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSASHINO MENEKI KENKYUSHO KK, Musashino Research Institute for Immunity Co Ltd filed Critical MUSASHINO MENEKI KENKYUSHO KK
Priority to JP2001267545A priority Critical patent/JP4864252B2/en
Publication of JP2003073315A publication Critical patent/JP2003073315A/en
Application granted granted Critical
Publication of JP4864252B2 publication Critical patent/JP4864252B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a composition manifesting an excellent effect by using a compound or a fraction having excellent anti-inflammatory effect obtained from vegetables which have been used in traditional medical treatment. SOLUTION: This composition manifesting excellent anti-inflammatory effect is obtained by formulating a new compound R-(-)-7-phenyl-hepta-4,6-diyn-2-ol which has anti-inflammatory effect, separated from vegetables belonging to Bidens genus or the vegetable belonging to Bidens genus including the compound, especially formulating Bidens pilosa or its extract.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は抗炎症性に優れた、しか
も細胞毒性の低い植物由来の有用成分に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a plant-derived useful ingredient having excellent anti-inflammatory properties and low cytotoxicity.

【0002】[0002]

【従来の技術及び発明が解決しようとする課題】外傷、
骨折、各種内臓疾患等において、感染の有無に拘らず生
体防衛反応として炎症を伴うことがしばしばである。炎
症は発熱や腫脹、さらに痛みを伴い、炎症を鎮めること
は古来そして現代においても重要な医療手段である。抗
炎症薬としてはコルチゾンに代表されるステロイド化合
物や、アスピリンに始まる各種の非ステロイド性消炎鎮
痛薬が多種あるものの、いずれもかなり強い副作用を伴
い、理想的な抗炎症薬はまだ人類の手中に入っていない
というのが実情である。
2. Prior Art and Problems to be Solved by the Invention
In bone fractures, various internal organ diseases, etc., inflammation is often accompanied as a biological defense reaction regardless of the presence or absence of infection. Inflammation is accompanied by fever, swelling, and pain, and quenching inflammation has been an important medical tool in ancient times and in modern times. Although there are various steroid compounds such as cortisone and various non-steroidal anti-inflammatory drugs starting with aspirin as anti-inflammatory drugs, they all have fairly strong side effects, and the ideal anti-inflammatory drug is still in the human hands. The reality is that it is not included.

【0003】本発明は、古来各種炎症性疾患の治療に民
間薬として広範に使用されてきた植物の中から、極めて
安全性が高く抗炎症効果に優れた植物であるBiden
spilosaの主要な抗炎症作用物質と見做される成
分を新たに分離しえたので、本化合物を含有する作用の
穏やかな経口消炎剤を提供しようとするものである。
[0003] The present invention, from the plants that have been widely used as a folk medicine in the treatment of ancient various inflammatory diseases, a plant which is extremely excellent in high safety anti-inflammatory effects Biden
Since the components considered to be major anti-inflammatory agents of spirosa can be newly separated, it is intended to provide an oral anti-inflammatory agent having a mild action, which contains the present compound.

【0004】[0004]

【課題を解決するための手段】本発明の化合物は、キク
科センダングサ属植物のBidens pilosa
ら発見された文献未載の新規化合物である。Biden
pilosaで代表されるキク科センダングサ属植
物は、特願2000−105559に詳述したように、
種類も多岐に亘り互いに交配するので変種も多く、植物
学上も混乱が見られ、学名、和名、漢名、の対応も交錯
していて同定することは極めて困難であるが、本発明で
用いられるセンダングサ属植物は以下に掲げるものを包
含する。
The compound of the present invention is a novel compound not found in the literature, which was discovered from Bidens pilosa, a plant of the genus Sengangusa, belonging to the Asteraceae family. Biden
s Asteraceae Bidens plant, which is represented by pilosa, as described in detail in Japanese Patent Application No. 2000-105559,
Since there are many varieties because they cross with each other over a wide variety of species, botany is also confusing, and scientific names, Japanese names, Chinese names are also difficult to identify because they correspond to each other, but in the present invention The plants of the genus Sengangusa used include those listed below.

【0005】Bidens pilosa L.(コセ
ンダングサ、コシロノセンダングサ、咸豊草)Bidens pilosa L.var.minor
(Blume)Sherff(シロバナセンダングサ、
シロノセンダングサ、コシロノセンダングサ、コセンダ
ングサ、咸豊草)Bidens pilosa L.var.biset
osa Ohtaniet Suzuki(アワユキセ
ンダングサ)Bidens pilosa L.f.decumbe
ns Scherff(ハイアワユキセンダングサ)Bidens pilosa L.var.radia
ta Scherff(タチアワユキセンダングサ、ハ
イアワユキセンダングサを含むこともある)Bidens pilosa L.var.radia
ta SchultzBipontinus(シロノセ
ンダングサ、オオバナノセンダングサ)Bidens biternata Lour.Mer
rill et Scherff(センダングサ)Bidens bipinnata L.(コバノセン
ダングサ、センダングサ)Bidens cernua
L.(ヤナギタウコギ)Bidens frondosa L.(アメリカセン
ダングサ、セイタカタウコギ)Bidens parviflora Willd(ホ
ソバノセンダングサ)Bidens radiata Thuill.va
r.pinnatifida (Turcz.)Kit
amura(エゾノタウコギ)Bidens tripartita L.(タウコ
ギ)
Bidens pilosa L. (Kosendangsa, Koshironosendangsa, Kama Toyokusa) Bidens pilosa L. var. minor
(Blume) Sherff
Bidens pilosa L. var. biset
osa Ohtani et Suzuki ( Ayuyukisen Dangusa) Bidens pilosa L. f. decumbe
ns Scherff Bidens pilosa L. var. radia
ta Scherff (May contain Tachiawa Yukisen Dangusa, Hiawayu Yukisen Dangusa) Bidens pilosa L. var. radia
ta Schultz Bipontinus (Shironosen Dangusa, Scutellaria baicalensis) Bidens biternata Lour. Mer
roll et Scherff Bidens bipinnata L. (Kobano Sengakusa, Sengakusa) Bidens cernua
L. (Willow Taukogi) Bidens frontosa L. (Bidens frondosa, Say Takata Acanthopanax) Bidens parviflora Willd (e buckwheat Roh Bidens) Bidens radiata Thuill. va
r. pinnatifida (Turcz.) Kit
amura (Ezonotaucogi) Bidens tripartita L. (Taukogi)

【0006】この植物は中国・台湾では主に咸豊草と呼
ばれるが異名も多く、同治草、鬼針草、三葉鬼針草、三
葉刺針草、刺針草、婆婆針草、白花婆婆針、蝦箝草、符
因草、符因頭、赤査某、金盞銀盤、含風草、南風草、蝦
公鋏、羞査某仔等の名があり、それぞれがどの学名に相
当するのかは明らかでない。
[0006] This plant is mainly referred to as Hamofusa in China / Taiwan, but it has many synonyms. It is also known as Dojisou, Oni Needle grass, Mitsui Oni grass, Trifoliat needle grass, Stab needle grass, Born needle grass, White flower There are names such as 蝦 箝 草, 腦 草, 绖 脤, Akasai, Kingokubanban, Fukaso, Minamifusa, 蝦 Kosashi, and Kazuko, and which scientific name each corresponds to. Not clear.

【0007】花はキク科特有の形で、白色または黄色の
丸みのある花弁のような舌状花が数個、中央には黄褐色
の管状花が多数集合している。中には舌状花を欠くもの
もある。茎は四角で薄紫に着色した節がある。3つまた
は5つに羽状に分かれた葉には柄があり、縁にはぎざぎ
ざがあって対生しているものが多い。
The flower has a shape peculiar to the Asteraceae, and several tongue-shaped flowers such as white or yellow rounded petals, and a large number of yellow-brown tubular flowers gather in the center. Some lack the tongue-shaped flower. The stem is square and has knots colored light purple. The leaves, which are divided into three or five feathers, have a handle, and are often opposite to each other with jagged edges.

【0008】日本では本州の暖地以南で見られ、台湾、
中国ないし世界の熱帯各地に分布し、草丈は25cm〜
約1mにもなり、通常一年草であるが温暖な気候条件に
恵まれると越冬し、花は一年中次々と咲く。動物や人の
衣服に付いて運ばれる黒褐色の種子の上部に逆棘のある
針があり、針の数も交配のため一定しないものが多い。
中国では鬼針草属と呼ばれている。
In Japan, it is found south of the warm regions of Honshu, in Taiwan,
Distributed in China and other tropical regions of the world, the plant height is 25 cm ~
It is about 1 m long and usually winters if it is an annual plant, but if it is blessed with mild climate conditions, the flowers bloom one after another all year round. There are needles with barbs on the top of black-brown seeds that are carried along with the clothes of animals and humans, and the number of needles is often not constant due to mating.
In China, it is called the Onirushusa genus.

【0009】センダングサ属植物とくにBidens
pilosaは古来伝承薬として、全草が糖尿病や炎症
性疾患、各種消化器病、各種感染症、リウマチ、等の治
療に、アフリカ、中南米、アジア等世界の熱帯〜温帯地
域で広く使われてきた。例えば台湾では急・慢性虫垂
炎、腎炎、胃腸炎、下痢、インフルエンザ、咽頭炎、歯
痛、肝炎、十二指腸炎に広く用いられ、肝臓の保護作用
があるとされている。アフリカでは傷の治療や重症悪阻
(おそ)、胃痛、便秘、腸内寄生虫、赤痢、下痢、腹痛等
に使われてきた。葉の搾汁は火傷や結膜炎、耳炎、さら
に止血剤にも用いるという。磨砕した汁や根の料理はマ
ラリアに効くと言われ、ズールー族では新芽を噛んでリ
ウマチの薬としている。中国では腸炎、桿菌赤痢、咽頭
炎に使われ、この植物を砕きあるいは煎じて傷の治療や
慢性潰瘍に使用される。中央アメリカの島々では搾汁を
目薬に、ベネズエラやブラジルでは潰瘍に、ボリビアの
アンデスでは血圧を下げるのに使う。また利尿や胆汁分
泌促進、風疹や猩猴熱の解熱にも用いる。
Plants of the genus Spendanga , especially bidens
Since ancient times, pilosa has been widely used in the tropical and temperate regions of Africa, Latin America, Asia, etc. for the treatment of diabetes, inflammatory diseases, digestive diseases, infectious diseases, rheumatism, etc. . For example, in Taiwan, it is widely used for acute and chronic appendicitis, nephritis, gastroenteritis, diarrhea, influenza, pharyngitis, toothache, hepatitis, and duodenitis, and is said to have a protective effect on the liver. In Africa, wound healing and severe emesis
It has been used for stomachache, constipation, intestinal parasite, dysentery, diarrhea, abdominal pain, etc. Leaf juice is said to be used for burns, conjunctivitis, otitis, and even hemostatic agents. It is said that ground soup and root dishes are effective against malaria, and the Zulu tribe chews the shoots and uses them as rheumatic drugs. In China, it is used for enteritis, bacillary dysentery, and pharyngitis, and the plant is crushed or decocted to be used for wound healing and chronic ulcers. On the islands of Central America, juice is used as an eye drop, on ulcers in Venezuela and Brazil, and in the Andes of Bolivia to lower blood pressure. It is also used to promote diuresis, biliary secretion, and antipyretic rubella and pyorax.

【0010】発明者等は本植物のエキスにつき、TPA
(12−O−tetradecanoylphorbo
l−13−acetate)誘発マウス耳介浮腫抑制試
験を行なって、対照に用いたインドメタシンに匹敵する
抑制効果を認めたことから、本植物の抗炎症作用物質の
単離精製を試み、その作用を代表すると思われる化合物
を得ることができた。以下、その経過を説明する。
The inventors of the present invention have obtained the TPA for the extract of this plant.
(12-O-tetradecanoylphorbo
1-13-acetate) -induced mouse ear edema inhibition test was performed, and an inhibitory effect comparable to that of indomethacin used as a control was observed. Therefore, isolation and purification of an anti-inflammatory agent of this plant was attempted, and its action was investigated. It was possible to obtain the compounds which are considered to be representative. The process will be described below.

【0011】[0011]

【実験1】マウス耳介浮腫抑制試験Bidens pilosaの地上部の乾燥物7kgを
酢酸エチル80Lで抽出し、抽出液を濃縮乾燥して14
9gのエキス(A)を得た。その残渣をメタノール20
Lで抽出し、抽出液を濃縮乾燥して238gのエキス
(B)を得た。陽性対照には非ステロイド性抗炎症薬で
あるインドメタシンを用いた。
[Experiment 1] Mouse ear edema inhibition test 7 kg of dried above ground parts of Bidens pilosa were extracted with 80 L of ethyl acetate, and the extract was concentrated and dried to obtain 14
9 g of extract (A) was obtained. The residue is methanol 20
It was extracted with L, and the extract was concentrated and dried to obtain 238 g of extract (B). Indomethacin, a non-steroidal anti-inflammatory drug, was used as a positive control.

【0012】1群3匹の6週齢ddY系雄性マウスを用
い、各検体をマウス右耳の内側と外側にそれぞれ0.5
mgずつ計1mgを塗布した。その30分後にTPAを
検体と同様に耳介の両面に1μgずつ塗布し、TPAに
よる浮腫が最高となる5時間後に耳の厚さを測定して対
照群との比較で抑制率を算出した。
Six 6-week-old male ddY mice of 1 group were used, and each sample was placed on the inside and outside of the right ear of the mouse by 0.5.
A total of 1 mg was applied per mg. Thirty minutes after that, 1 μg of TPA was applied to both surfaces of the auricle in the same manner as the sample, and 5 hours after the edema due to TPA reached its maximum, the ear thickness was measured and the inhibition rate was calculated by comparison with the control group.

【0013】 対照群 インドメタシン群 エキス(A)群 エキス(B)群 抑制率(%) 0.0 79.4 53.3 79.1 Control group Indomethacin group Extract (A) group Extract (B) group Inhibition rate (%) 0.0 79.4 53.3 79.1

【0014】また非ステロイド性抗炎症薬であるアスピ
リンの常用者には大腸癌の発生が少ないという疫学的調
査報告がある。前記のようにBidens pilos
には強い抗炎症作用があることから、大腸癌抑制の一
次スクリーニングとしてマウス大腸異常腺窩巣(発癌性
物質等を投与することによって生じる大腸の病変、AC
F)に対する抑制効果を試験したところ、この植物のエ
キスは陽性対照群として用いたピロキシカムと同等ある
いはそれ以上の抑制効果を示した。
There is also an epidemiological investigation report that colon cancer is rarely generated in normal users of aspirin, which is a nonsteroidal anti-inflammatory drug. As mentioned above, Bidens pilos
Since a has a strong anti-inflammatory effect, abnormal colon crypts in the mouse large intestine (a lesion of the large intestine caused by administration of a carcinogen etc.
When the inhibitory effect against F) was tested, the extract of this plant showed an inhibitory effect equivalent to or higher than that of piroxicam used as a positive control group.

【0015】[0015]

【実験2】アゾキシメタン誘発大腸異常腺窩巣に対する
抑制試験 1群6匹の6週齢ddY系雄性マウスを用い、1週間の
予備飼育の後、体重kgあたり10mgのアゾキシメタ
ン(AOM)を右下肢皮下に週1回ずつ2週間投与し
た。Bidens pilosaのヒト常用量を1日3
gとしてその5倍量相当の前記エキスA及びBを1日分
の飲水に溶解して、AOM初回投与の前日から飲ませ
た。陽性対照にはピロキシカムをヒト1日常用量0.6
gの計算で飲水に溶解して与えた。AOM第一回投与か
ら4週間後に大腸を摘出し、ホルマリンで伸展固定後メ
チレンブルーで染色される大腸異常腺窩巣を顕微鏡下で
計測した。
[Experiment 2] Inhibition test on abnormal colonic crypts induced by azoxymethane Using 6 6-week-old male ddY mice in 1 group, after preliminarily breeding for 1 week, 10 mg of azoxymethane (AOM) per kg of body weight was subcutaneously injected into the right lower limb. Was administered once a week for 2 weeks. Daily human dose of Bidens pilosa 3 times daily
The extract A and B corresponding to 5 times as much as g were dissolved in drinking water for one day and drunk from the day before the first administration of AOM. Piroxicam was used as a positive control in humans at a daily dose of 0.6
It was given by dissolving in drinking water in the calculation of g. After 4 weeks from the first administration of AOM, the large intestine was removed, and after extension and fixation with formalin, abnormal colonic foci stained with methylene blue were measured under a microscope.

【0016】 対照群 ピロキシカム群 エキス(A)群 エキス(B)群 抑制率(%) 100 60.3 52.4 61.7 Control group Piroxicam group Extract (A) group Extract (B) group Inhibition rate (%) 100 60.3 52.4 61.7

【0017】次に、一酸化窒素(NO)は生体内におい
ては循環系や神経系における情報伝達のほか、感染・炎
症・免疫反応のメディエーターとして、またアポトーシ
スの制御や発がんにも関与するなど極めて多彩な機能を
持つことが近年次第に明らかになってきた。特に炎症反
応においてNO合成酵素が誘導されてNOが過剰に生産
され、これが活性酸素や金属イオンの作用で反応性窒素
酸化物となって条件により炎症を増悪し、あるいは炎症
を抑制するとされている。Bidens pilosa
はシクロオキシゲナーゼ阻害作用を持つことが報告され
ており、シクロオキシゲナーゼを阻害することによって
プロスタグランディンの合成を抑制し抗炎症作用を発揮
するものと考えられる。またNOはシクロオキシゲナー
ゼを活性化する作用があり、NO産生を抑制することは
プロスタグランディンの合成が抑制されることになる。
したがってNOの産生を抑制する物質は抗炎症作用を持
つと期待されている。
Next, nitric oxide (NO) plays an important role as a mediator of infection, inflammation, and immune reaction in the living body, in addition to information transmission in the circulatory system and nervous system, and is involved in the control of apoptosis and carcinogenesis. In recent years, it has become clear that it has various functions. In particular, it is said that NO synthase is induced in an inflammatory reaction and NO is excessively produced, and this becomes reactive nitrogen oxides by the action of active oxygen and metal ions, and exacerbates or suppresses inflammation depending on conditions. . Bidens pilosa
Has been reported to have a cyclooxygenase inhibitory action, and it is considered that by inhibiting cyclooxygenase, it inhibits the synthesis of prostaglandin and exerts an anti-inflammatory action. Further, NO has an action of activating cyclooxygenase, and suppressing NO production results in suppression of prostaglandin synthesis.
Therefore, substances that suppress NO production are expected to have anti-inflammatory effects.

【0018】これまでBidens pilosaから
見出だされた成分としては、ポリアセチレン化合物やフ
ラボノイド化合物が数多く報告されている。キク科の植
物はあらゆる部位にポリアセチレン化合物が存在するこ
とが知られており、ある種のポリアセチレン化合物やフ
ラボノイド化合物には抗炎症性があることも知られてい
る。Bidens pilosaは多くの炎症性疾患に
民間薬として広く用いられているにも拘らず、また、
idens pilosaから多くの化合物が分離され
ているにも拘らず、抗炎症成分として有力な化合物はま
だ証明されていない。そこで発明者は前記NO産生の阻
害活性を抗炎症活性の指標として測定することにより、
有効成分を検索しようと考えた。測定法としてはマクロ
ファージ様細胞株(RAW264)を、検体試料存在下
でLPSで刺激し、Griess試薬を用いて培養上清
中のNO2 量を測定した。またマクロファージの生存率
はMTT法で測定した。
Many polyacetylene compounds and flavonoid compounds have been reported as components found in Bidens pilosa . It is known that a plant of the Asteraceae family has a polyacetylene compound at every site, and it is also known that certain polyacetylene compounds and flavonoid compounds have anti-inflammatory properties. Bidens pilosa is despite widely used as a folk medicine in many inflammatory diseases, also, B
Despite the large number of isolated compounds from idens pilosa , no potent compound has been proved as an anti-inflammatory component. Therefore, the inventor measured the inhibitory activity of NO production as an index of anti-inflammatory activity,
I thought about searching for active ingredients. As a measuring method, a macrophage-like cell line (RAW264) was stimulated with LPS in the presence of a specimen sample, and the amount of NO 2 in the culture supernatant was measured using a Griess reagent. The survival rate of macrophages was measured by the MTT method.

【0019】その結果、酢酸エチルエキス(A)にメタ
ノールエキス(B)よりも強いNO産生阻害活性が認め
られ、濃度により細胞毒性は緩和されつつもなお強いN
O産生阻害活性を示した。
As a result, the ethyl acetate extract (A) was found to have a stronger NO production inhibitory activity than the methanol extract (B), and depending on the concentration, the cytotoxicity was alleviated but the N content was still strong.
It exhibited O production inhibitory activity.

【0020】[0020]

【実験3】NO産生阻害活性の測定 RAW264細胞株は、仔牛血清(FBS)5%、ペニ
シリン50U/mL、ストレプトマイシン50μg/m
L、L−グルタミン20mMを含むRPMI−1640
培地で37℃、5%炭酸ガス存在下で培養した。細胞数
1×106 /mLのRAW264細胞を96穴のプレー
トに100μLずつ分注し、4時間培養後、試料を加え
た培地100μLと、蒸留水に溶かしたLPS(0.4
mg/mL)10μLを加えた。24時間培養後、培養
上清100μLを採取し、これにGriess試薬(サ
ルファニルアミド1%、ナフチルエチレンジアミン0.
1%、3%リン酸溶液)を加え、室温で10分放置後5
40nmで吸光度を測定し(対照700nm)、亜硝酸
Naにより求めた検量線でNO2 量を測定した。
[Experiment 3] Measurement of NO production inhibitory activity The RAW264 cell line was 5% fetal bovine serum (FBS), 50 U / mL penicillin, and 50 μg / m streptomycin.
RPMI-1640 containing 20 mM of L, L-glutamine
The cells were cultured at 37 ° C in the presence of 5% carbon dioxide gas. RAW264 cells with a cell number of 1 × 10 6 / mL were dispensed into a 96-well plate by 100 μL each, and after culturing for 4 hours, 100 μL of a medium containing a sample and LPS (0.4%) dissolved in distilled water.
mg / mL) 10 μL was added. After culturing for 24 hours, 100 μL of the culture supernatant was collected, and Griess reagent (sulfanilamide 1%, naphthylethylenediamine 0.
1%, 3% phosphoric acid solution) was added and left at room temperature for 10 minutes, then 5
Absorbance was measured at 40 nm (control 700 nm), and NO 2 amount was measured by a calibration curve obtained by Na nitrite.

【0021】マクロファージの生細胞数(生存率の測
定)は、3−(4,5−dimethylthiazo
l−2−yl)−2,5−diphenyl−tetr
azoliumbromide(MTT)による比色計
法で測定した。すなわち、NO測定のために100μL
の上清を採取した残りにMTT(5mg/mL inP
BS(−))10μLを加え、37℃、30分間保温し
た後、培地を除去し、100μLのDMSOを加えて室
温で10分間放置後、540nm(対照700nm)の
吸光度を測定して生細胞数を求めた。
The number of viable cells of macrophages (measurement of survival rate) is 3- (4,5-dimethylthiozo).
l-2-yl) -2,5-diphenyl-tetr
It was measured by a colorimetric method using azolumbromide (MTT). That is, 100 μL for NO measurement
Of the supernatant of MTT (5 mg / mL inP
After adding 10 µL of BS (-) and incubating at 37 ° C for 30 minutes, the medium was removed, 100 µL of DMSO was added, and the mixture was allowed to stand at room temperature for 10 minutes, and then the absorbance at 540 nm (control 700 nm) was measured to determine the number of viable cells. I asked.

【0022】 μg/mL NO産生比 細胞生存率 対 照 −−− 100 100 エキスA 100 8.2 51.4 50 26.1 94.0 25 59.5 97.0 エキスB 100 66.6 98.9 50 77.9 94.9 25 92.4 89.1 Μg / mL NO production ratio Cell viability vs. 100 100 Extract A 100 8.2 51.4 50 26.1 94.0 25 59.5 97.0 Extract B 100 66.6 98. 9 50 77.9 94.9 25 92.4 89.1

【0023】[0023]

【実験4】活性成分の分離 クロロフィルを除くためにエキスA116gを活性炭7
5gに吸着させ、アセトン/酢エチ/THFで順次溶出
し、アセトン/酢エチ画分をさらにシリカゲル上で
ヘキサン/酢エチ混液の濃度を[10/1]→→→[1
/2]まで逐次変化させ、次に酢エチ単独、酢エチ/メ
タノール[1/1]、メタノール単独へと逐次変えなが
ら傾斜溶出した。
[Experiment 4] Separation of active ingredient 116 g of extract A was added to activated carbon 7 to remove chlorophyll.
It was adsorbed on 5 g and eluted with acetone / ethyl acetate / THF sequentially, and the acetone / ethyl acetate fraction was further n-
Change the concentration of hexane / vinegar ethyl mixture [10/1] →→→ [1
/ 2], and then gradient elution was performed while sequentially changing to ethyl acetate alone, ethyl acetate / methanol [1/1], and methanol alone.

【0024】NO産生阻害活性でモニターしながら活性
の比較的強い画分をさらにLH20カラム上でメタノー
ルで分画溶出し、その中でまた活性の強い画分をシリカ
ゲルカラム上で−ヘキサン/酢エチ混液の濃度を[2
0/1]→→→[1/2]まで逐次変化させ、次に酢エ
チ単独、酢エチ/メタノール[2/1]→→→[1/
2]、メタノール単独まで逐次変えながら傾斜溶出し
た。さらに活性の強い画分を今度は順相HPLC(se
nshu PAK Silica−4251−N10φ
×250mm)で−ヘキサン/酢エチ[7/3]を用
い毎分5mLの流速で分画し、10.7分の所でUV2
54nmのピークとして101mgの化合物Xを得た。
While monitoring the NO production inhibitory activity, the fraction having a relatively high activity was further fractionally eluted with methanol on an LH20 column, and the fraction having a strong activity was further eluted with n -hexane / vinegar on a silica gel column. Change the concentration of the ethylene mixture [2
0/1] →→→ sequentially changes to [1/2], then ethyl acetate alone, ethyl acetate / methanol [2/1] →→→ [1 /
2], gradient elution was performed while sequentially changing to methanol alone. The more active fraction was analyzed by normal phase HPLC (se
nshu PAK Silica-4251-N10φ
X 250 mm) and fractionated with n -hexane / ethyl acetate [7/3] at a flow rate of 5 mL / min, and UV2 at 10.7 minutes
101 mg of compound X was obtained as a peak at 54 nm.

【0025】化合物Xは無色油状の物質で光によって黄
色に変化した。EI−MSより分子量184、HR−M
Sよりm/z=184.0889で理論値と一致し、分
子式はC1312Oと推定した。
Compound X was a colorless oily substance and turned yellow by light. From EI-MS, molecular weight 184, HR-M
From S, m / z = 184.0889, which was in agreement with the theoretical value, and the molecular formula was estimated to be C 13 H 12 O.

【0026】1H−NMRで1.31ppm(3H,
d,=6.35)、2.19ppm(brs),2.
52ppm(1H,dd,=17.09,6.1
0),2.57ppm(1H,dd,=17.09、
5.62),4.03ppm(1H,ddd−lik
e,=5.62,6.10,6.35),7.28−
7.49ppm(5H,m)のシグナルが観察された。
[0026] In 1 H-NMR 1.31ppm (3H,
d, J = 6.35), 2.19 ppm (brs), 2.
52 ppm (1H, dd, J = 17.09, 6.1
0), 2.57 ppm (1H, dd, J = 17.09,
5.62), 4.03 ppm (1H, ddd-lik
e, J = 5.62, 6.10, 6.35), 7.28-
A signal of 7.49 ppm (5H, m) was observed.

【0027】1.31ppmはメチル基、2.19pp
mはアルコール性水酸基、7.28−7.49ppmは
一置換ベンゼン由来のシグナルと考えられる。また2.
52,2.57ppmは隣にメチン基が存在している非
等価なプロトン2つであり、ジェミナルで影響しあい、
さらに隣のプロトンと影響しあっていると推測される。
1.31 ppm is a methyl group, 2.19 pp
It is considered that m is an alcoholic hydroxyl group and 7.28-7.49 ppm is a signal derived from monosubstituted benzene. Also 2.
52 and 2.57 ppm are two non-equivalent protons having a methine group next to each other, and they affect each other by geminal.
Furthermore, it is presumed that the neighboring protons affect each other.

【0028】4.03ppmは値より1.31ppm
のメチル基と思われるシグナルと2.52ppm、2.
57ppmの非等価な2つのプロトンに隣接していると
考えられる。さらに13C−NMRより121.8ppm
の4級炭素、128.4,129.0,132.5pp
mの3級炭素のシグナル3本は一置換ベンゼンである。
22.5,30.1,66.4ppmはそれぞれ1級、
2級、3級炭素のシグナルである。また、67.4−8
0.7ppmに4級炭素のシグナルが4本存在し、これ
らの炭素は三重結合で繋がっていると考えられた。 1
1HCOSY, 1H−13CCOSY,INADEQU
ATE,HMBC等2D−NMRスペクトルを検討した
ところ、4級炭素にはメチレン基およびベンゼン環が繋
がり、また、メチル基の隣にはメチン基、その隣にはメ
チレン基が結合していると推定された。これはデカップ
リングによっても証明された。
4.03 ppm is 1.31 ppm from J value
With a signal that seems to be the methyl group of 2.52 ppm, 2.
It is thought to be adjacent to two non-equivalent protons of 57 ppm. Furthermore, 121.8 ppm from 13 C-NMR
Quaternary carbon, 128.4, 129.0, 132.5pp
The three signals of the tertiary carbon of m are monosubstituted benzenes.
22.5, 30.1 and 66.4 ppm are 1st grade,
It is a signal of secondary and tertiary carbon. Also, 67.4-8
There were four quaternary carbon signals at 0.7 ppm, and it was considered that these carbons were connected by triple bonds. 1 H
1 HCOSY, 1 H− 13 CCOSY, INADEQU
When 2D-NMR spectra such as ATE and HMBC were examined, it was presumed that a methylene group and a benzene ring were connected to the quaternary carbon, a methine group was next to the methyl group, and a methylene group was next to the methyl group. Was done. This was also proved by decoupling.

【0029】MSスペクトルにおいて分子量は184、
ベースピークは140であった。一般に酸素原子の隣の
C−C結合は切れやすいことから、化合物Xの構造の第
2級アルコールが切れて140のフラグメントがベース
ピークとなって現れたものと考えられる。ベースピーク
以下のフラグメントは文献値と一致した。
In the MS spectrum, the molecular weight is 184,
The base peak was 140. In general, the C—C bond next to the oxygen atom is easily broken, so it is considered that the secondary alcohol in the structure of compound X is broken and the 140 fragment appears as a base peak. Fragments below the base peak matched the literature values.

【0030】 [化合物Xの 1H−NMRデータ] ppm H−1 1.31(3H,d,=6.35) H−2 4.03(1H,ddd−like, =5.62,6.10,6.35) H−3 2.52(1H,dd,=17.09,6.10) 2.57(1H,dd,=17.09,5.62) H−2′〜6′ 7.28−7.49(5H,m) 2 −OH 2.19(brs) スペクトルはCDCl3 中400MHzで測定 データはTMSからのppmで表示[ 1 H-NMR Data of Compound X] ppm H-1 1.31 (3H, d, J = 6.35) H-2 4.03 (1H, ddd-like, J = 5.62, 6.10, 6.35) H-3 2.52 (1H, dd, J = 17.09, 6.10) 2.57 (1H, dd, J = 17.09, 5.62) H-2 '~6' 7.28-7.49 (5H, m ) C 2 -OH 2.19 (brs) spectra in ppm from measurement data TMS in CDCl 3 400 MHz

【0031】 [化合物Xの13C−NMRデータ] ppm スペクトルはCDCl3 中100MHzで測定 1 22.5 q データはTMSからのppmで表示 2 66.4 d 3 30.1 t 4 80.7 s 5 74.0 s 6 67.4 s 7 75.4 s 1′ 121.8 s 2′ 132.5 d 3′ 128.4 d 4′ 129.0 d 5′ 128.4 d 6′ 132.5 d [ 13 C-NMR Data of Compound X] ppm spectrum measured in CDCl 3 at 100 MHz 1 22.5 q data expressed in ppm from TMS 2 66.4 d 3 30.1 t 4 80.7 s 5 74.0 s 6 67.4 s 7 75.4 s 1 '121.8 s 2' 132.5 d 3 '128.4 d 4' 129.0 d 5 '128.4 d 6' 132.5 d

【0032】次に、化合物Xの2級水酸基の配位を決め
るべく、新モッシャー法を用いて絶対配置を決定した。
Next, in order to determine the coordination of the secondary hydroxyl group of compound X, the absolute configuration was determined using the new Mosher method.

【0033】まず、化合物X(6.8mg)にピリジン
125μL、R−(−)−α−methoxy−α−t
rifluoromethyl−phenylacet
icacid chloride[R−(−)MTP
A]37μLを加え、室温にて24時間撹拌を行った。
反応終了後、溶媒を留去し、−ヘキサン:酢エチ=
2:1を溶出溶媒としたHPLCを用いて精製した結
果、6.8mgの(−)−MTPAエステル体を得た。
同様に、化合物X(6.8mg)にピリジン125μ
L、S−(+)−α−methoxy−α−trifl
uoromethyl−phenylacetic a
cid chloride[S−(+)MTPA]37
μLを加え、同様の操作を行い、対応する(+)−MT
PAエステル体を得た。
First, 125 μL of pyridine and R-(−)-α-methoxy-α-t were added to compound X (6.8 mg).
rifluoromethyl-phenylacet
icacid chloride [R-(-) MTP
A] 37 μL was added, and the mixture was stirred at room temperature for 24 hours.
After completion of the reaction, the solvent was distilled off, and n -hexane: ethyl acetate =
As a result of purification using HPLC with 2: 1 as an elution solvent, 6.8 mg of (−)-MTPA ester was obtained.
Similarly, compound X (6.8 mg) was added to pyridine 125 μm.
L, S-(+)-α-methoxy-α-trifl
uoromethyl-phenylacetic a
cid chloride [S-(+) MTPA] 37
Add μL and perform the same operation to get the corresponding (+)-MT
A PA ester was obtained.

【0034】次にこれらの(+)および(−)MTPA
エステルについて、それぞれ 1H−NMRによりプロト
ンの帰属を行い、Δδ{=δ(−)−δ(+)}値を求
めた。
Next, these (+) and (-) MTPAs
For each ester, protons were assigned by 1 H-NMR, and the Δδ {= δ (−) − δ (+)} value was obtained.

【0035】 [ 1H−NMRスペクトルデータおよびΔδ値] (−)MTPAエステル (+)MTPAエステル Δδ値 H−1 1.471 1.386 0.085 H−3 2.699 2.703 −0.004 2.648 2.651 −0.003 [ 1 H-NMR spectrum data and Δδ value] (−) MTPA ester (+) MTPA ester Δδ value H-1 1.471 1.386 0.085 H-3 2.699 2.703-0. 004 2.648 2.651 -0.003

【0036】MTPAを上側で手前、カルビノールプロ
トン(MTPAエステル酸素の付け根のプロトン)を下
側で手前とし、Δδ>0のプロトングループを右側、Δ
δ<0のプロトングループを左側に置くと2位の炭素に
おける立体配置はRと判明した。
MTPA is on the upper side, carbinol proton (proton at the base of MTPA ester oxygen) is on the lower side, and the proton group with Δδ> 0 is on the right side, Δδ> 0.
When the proton group with δ <0 was placed on the left side, the configuration at the carbon at position 2 was found to be R.

【0037】この結果からR配置であるということが明
白となり、化合物Xの構造は、[α]D 23の値が−3
4.7゜(c=0.28,EtOH)であるということ
から、R−(−)−7−phenylhepta−4,
6−diyn−2−ol(X)であると決定した。
From this result, it is clear that the compound has the R configuration, and the structure of the compound X has a value of [α] D 23 of −3.
Since it is 4.7 ° (c = 0.28, EtOH), R-(−)-7-phenylhepta-4,
It was determined to be 6-diyn-2-ol (X).

【0038】[化合物X] [Compound X]

【0039】なお化合物Xは、Ming−Huey C
hangらがBidens pilosa L. va
r. minor (Blume)Sherffから単
離してpilosolAと名付けた化合物(J.Chi
n.Chem.Soc.47,1131,2000)と
極めて近似した構造であるが、pilosolAは
[α]D 26の値が全く逆で、+6゜(c=0.1,Me
OH)と記載しており、更に不斉炭素の絶対配置は決定
されていない。これらのことから化合物Xはpilos
olAとは異なる化合物と考えられる。
The compound X is Ming-Huey C
hang et al. in Bidens pilosa L .; va
r. A compound isolated from minor (Blume) Sherff and named pilosolA (J. Chi
n. Chem. Soc. 47, is a structure in which very close and 1131,2000), pilosolA the [alpha] value of D 26 is exactly the reverse, + 6 ° (c = 0.1, Me
OH) and the absolute configuration of the asymmetric carbon has not been determined. From these facts, compound X is pilos
It is considered to be a compound different from olA.

【0040】 [化合物XのNO産生阻害活性] μg/mL NO産生比 細胞生存率 対 照 −−− 100 100 化合物X 100 0.0 0.5 〃 〃 50 4.5 72.7 〃 〃 25 40.0 91.9 〃 〃 12.5 47.7 99.8 [NO Production Inhibitory Activity of Compound X] μg / mL NO Production Ratio Cell viability vs. 100 100 Compound X 100 0.0 0.5 0.5 〃 〃 50 4.5 72.7 〃 〃 25 40 0.0 91.9 〃 〃 12.5 47.7 99.8

【0041】以下実施例により本発明を具体的に説明す
るが、本発明はこれらに限定されるものではない。
The present invention will be specifically described below with reference to examples, but the present invention is not limited thereto.

【0042】[0042]

【実施例1】健康茶の調製 清浄栽培したBidens pilosaの地上部を収
穫し、洗浄裁断後、30分間蒸煮殺菌して熱風乾燥した
ものを細かく刻み、焙煎した大麦と等量ずつ混合し、約
4%のショウガ粉末を加えて香味を調整した。これをテ
ィーバッグに約3gずつ分包して健康茶とした。本品は
ティーバッグ1包を1〜1.2Lの水を加え沸騰してか
ら約5分間煎じると香ばしくてクセのない、しかも飽き
のこない日常飲用の健康茶として好適である。この健康
茶の効果を示唆する例を示すと実施例2〜4のようであ
る。
[Example 1] Preparation of healthy tea The above-ground portion of bidens pilosa cultivated cleanly was harvested, washed and cut, sterilized by steaming for 30 minutes, hot air dried, finely chopped, and mixed with roasted barley in equal amounts, The flavor was adjusted by adding about 4% ginger powder. Approximately 3 g of each was packaged in a tea bag to give healthy tea. This product is suitable as a healthy tea for daily drinking, which is fragrant, has no habit, and does not get tired when 1 tea bag is added with 1 to 1.2 L of water and boiled for about 5 minutes. Examples suggesting the effect of this health tea are as in Examples 2 to 4.

【0043】[0043]

【実施例2】ここに挙げる4例は、医師の診察を受けて
乳幼児アトピー性皮膚炎と診断されたものの、母親が薬
剤を忌避して、塗り薬を使用せず、実施例1の健康茶を
体温程度の温度で、表記のように投与した例である。い
ずれの例もこの間に排便の回数も増え、便の状態も改善
が見られた。
[Example 2] In the four cases listed here, although a baby was diagnosed with atopic dermatitis by the medical examination, the mother avoided the drug and did not use the ointment. This is an example of administration as shown at a temperature of about body temperature. In all cases, the frequency of defecation increased during this period, and the condition of the stools also improved.

【0044】[例1]乳幼児アトピー性皮膚炎 氏名年齢:O.A.、3カ月女 発症部位:顔・耳・頸の周囲、四肢の付根や関節部 投与法:授乳前毎回30〜40mL、入浴前後毎回50
〜60mL 1日量:計約10回、約400mL 経 過:1カ月で顔・耳、2カ月で頸の症状消退、3
〜4カ月でほぼ完治
[Example 1] Infant atopic dermatitis Name Age: O. A. 3 months Female onset site: around face / ear / neck, root of limbs and joint administration method: 30-40 mL before lactation, 50 before and after bathing
~ 60mL Daily dose: About 10 times in total, about 400mL Over time: Face / ear in 1 month, cervical symptoms disappeared in 2 months, 3
~ 4 months almost completely cured

【0045】[例2]乳幼児アトピー性皮膚炎 氏名年齢:K.A.、4カ月女 発症部位:耳・頸・頬・腕の関節部 投与法:就眠前・授乳前毎回30〜60mL 1日量:計約10回、約500mL 経 過:約2週間でまず頬が、約5週間で他の部位の
症状もほとんど消失
[Example 2] Infant atopic dermatitis Name Age: K. A. 4 months Female onset site: Ear, neck, cheek, arm joint administration method: Before sleeping / before breastfeeding 30-60 mL each time Daily dose: About 10 times in total, about 500 mL After: About 2 weeks cheeks first , The symptoms of other parts almost disappeared in about 5 weeks

【0046】[例3]乳幼児アトピー性皮膚炎 氏名年齢:T.B.、1歳半女 発症部位:手・腕・顔・ふくらはぎ 投与法:随時 1日量:計10回以上、1〜1.2L 経 過:約1カ月半で顔から発疹が消退し、他は1〜
2カ月遅れて消失その後半年になるが全く再発していな
い。
[Example 3] Infant atopic dermatitis Name: Age T. B. 1 year and a half woman Onset site: hand, arm, face, calf Administration method: As needed Daily dose: 10 times or more in total, 1 to 1.2 L Over time: The rash disappeared from the face in about one and a half months, and others 1 to
It disappeared two months later, but in the latter half of the year, it has not recurred at all.

【0047】[例4]乳幼児アトピー性皮膚炎 氏名年齢:0.C.、2歳半男 発症部位:耳・頸・腕・膝の裏 投与法:随時 1日量:計10回以上、1.5〜1.8L 経 過:約2カ月から発疹も痒みも次第に消退し3カ
月で完治その後半年になるが全く再発していない。
[Example 4] Infant atopic dermatitis Name Age: 0. C. 2-year-old and half-male Onset site: ear, neck, arm, and knee back administration method: As needed Daily dose: 10 times or more in total, 1.5 to 1.8 L Over time: From about 2 months, rash and itching gradually disappeared He was completely cured in three months, but in the latter half of the year, he had no recurrence.

【0048】[0048]

【実施例3】N.H.氏(男性、53歳)は発汗、入浴
後、運動後等により発症する蕁麻疹で、食物との因果関
係は否定されており、抗ヒスタミン剤の内服で症状を抑
えるよりなく、長年悩まされてきた。体質改善のため毎
朝30〜40分の速歩での散歩を取り入れると共に、実
施例1の健康茶を毎日10杯以上飲んでもらった。その
結果約半年後には蕁麻疹がほとんど出なくなった。
Third Embodiment H. Mr. (male, 53 years old) has urticaria that develops after sweating, taking a bath, and after exercise, and its causal relationship with food has been denied, and he has been troubled for many years instead of suppressing the symptoms by taking antihistamines. In order to improve his constitution, he took a quick walk for 30-40 minutes every morning, and had him drink 10 or more cups of the health tea of Example 1 every day. As a result, urticaria almost disappeared after about 6 months.

【0049】[0049]

【実施例4】K.K.氏(男性、29歳)は全身性の皮膚
炎で、医師から乾癬と診断され、1年ほど通院してステ
ロイド外用剤治療を受けたが改善しなかった。そこで実
施例1の健康茶を体温より少し高めで毎日コップ10杯
以上摂取してもらったところ、約2週間後には目のクマ
が消え、4〜5カ月経った頃から徐々に痒みが消退し、
半年後には全身的に症状が全く消失した。
Example 4 K. K. He (male, 29 years old) had systemic dermatitis and was diagnosed with psoriasis by his doctor. He went to the hospital for about a year and was treated with topical steroids, but did not improve. Therefore, when the healthy tea of Example 1 was taken at a temperature slightly higher than the body temperature and ingested more than 10 cups every day, the eye bear disappeared after about 2 weeks, and the itch gradually disappeared from about 4 to 5 months later. ,
Six months later, the symptoms disappeared systemically.

【0050】[0050]

【実施例5】Bidens pilosa乾燥物50k
gに熱水750Lを加えて約90℃で静置抽出し、固液
分離後残渣をさらに500Lの水で抽出、抽出液を併せ
て約40℃で30Lまで減圧濃縮してから噴霧乾燥して
12.1kgの乾燥エキスを得た。
Example 5 Bidens pilosa dried product 50k
750 L of hot water was added to g and static extraction was performed at about 90 ° C. After solid-liquid separation, the residue was further extracted with 500 L of water, and the extracts were combined and concentrated under reduced pressure to about 30 L at about 40 ° C. and then spray-dried. 12.1 kg of dried extract was obtained.

【0051】[0051]

【実施例6】実施例5で得た乾燥エキス1kgにアビセ
ル0.2kgを加えて300mgの錠剤とした。アルコ
ール性肝炎と診断された男性(45歳)に毎日4錠ずつ
投与したところ、3カ月後には全快した。 GOT GPT γGTP 投与前 80 64 73 投与後 38 33 20
Example 6 0.2 kg of Avicel was added to 1 kg of the dried extract obtained in Example 5 to give 300 mg tablets. When a man (45 years old) diagnosed with alcoholic hepatitis was administered 4 tablets daily, he recovered completely after 3 months. Before administration of GOT GPT γGTP 80 64 73 After administration 38 33 20

【0052】[0052]

【実施例7】Bidens pilosa乾燥物72k
gに10倍量の50%エタノールを加えて約50℃で8
時間加熱抽出後、一夜放置して瀘過し、瀘液を減圧下に
濃縮して凍結乾燥して13kgの乾燥エキスを得た。
Example 7 Bidens pilosa dried product 72k
Add 10 times amount of 50% ethanol to g and add 8 at about 50 ℃.
After extraction by heating for an hour, the mixture was left overnight and filtered, and the filtrate was concentrated under reduced pressure and freeze-dried to obtain 13 kg of dried extract.

【0053】[0053]

【実施例8】実施例7で得た乾燥エキス1kgを60L
の精製水に溶解し、10gの活性炭を添加撹拌して脱色
瀘過した液10%を含む薬用クリームを調整した。ボラ
ンティア10人の上腕の内側にラウリル硫酸ソーダ30
%水溶液を塗って5時間包帯を施したところ、全員が赤
く炎症を起こした。直ちに炎症部位にこのクリームを塗
り、就寝前と起床時にも同様に塗布したところ10人中
8人は翌朝、2人は翌翌朝にすっかり炎症が消退した。
[Example 8] 1 kg of the dried extract obtained in Example 7 was added to 60 L.
Was dissolved in purified water, and 10 g of activated carbon was added and stirred to prepare a medicated cream containing 10% of the decolorized and filtered solution. Sodium lauryl sulfate 30 inside the upper arms of 10 volunteers
% Water solution was applied and bandaged for 5 hours, all were red and inflamed. Immediately after applying this cream to the inflamed area and applying the same before going to bed and at waking up, 8 of 10 people completely disappeared in the morning of the following morning and 2 of the 10 people in the morning of the next morning.

【0054】[0054]

【実施例9】実施例7で得た乾燥エキス500gを生理
食塩水100Lに溶解して含嗽剤を調整した。風邪で扁
桃腺が腫れ、喉の発赤が認められたボランティア5人
に、この含嗽剤を1日5回使用させたところ、全員が翌
日には軽快し楽になったと報告した。
Example 9 500 g of the dried extract obtained in Example 7 was dissolved in 100 L of physiological saline to prepare an gargle. Five volunteers, who had swollen tonsils and redness in their throat, were given this mouthwash 5 times a day, and all of them reported that they became lighter and easier the next day.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 29/00 A61P 29/00 31/04 31/04 37/00 37/00 37/08 37/08 Fターム(参考) 4C088 AB26 AC02 BA07 BA08 CA03 MA34 MA52 MA63 NA14 ZA34 ZA42 ZA66 ZA67 ZA72 ZA75 ZA89 ZB11 ZB13 ZB35 ZB37 4C206 AA01 AA02 AA03 CA11 MA01 MA04 NA14 ZA34 ZA42 ZA66 ZA67 ZA72 ZA75 ZA89 ZB11 ZB13 ZB35 ZB37 4H006 AA01 AB22 FC52 FC80 FE11─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61P 29/00 A61P 29/00 31/04 31/04 37/00 37/00 37/08 37/08 F Terms (reference) 4C088 AB26 AC02 BA07 BA08 CA03 MA34 MA52 MA63 NA14 ZA34 ZA42 ZA66 ZA67 ZA72 ZA75 ZA89 ZB11 ZB13 ZB35 ZB37 4C206 AA01 AA02 AA03 CA11 MA01 MA04 NA14 ZA34 ZA62 ZB11B11B11B11B11B11B11B11B11B11ZA17BZABZA15ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA67ZA75ZA47ZA52

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】R−(−)−7−phenylhepta
−4,6−diyn−2−ol。
1. R-(-)-7-phenylhepta
-4,6-diyn-2-ol.
【請求項2】請求項1の化合物を含有するセンダングサ
属植物由来のエキス。
2. An extract derived from a plant of the genus Sengangusa containing the compound of claim 1.
【請求項3】請求項1の化合物を含有するセンダングサ
属植物自体または請求項2のエキスを含有する組成物。
3. A composition containing the plant of the genus Spendanga itself containing the compound of claim 1 or the extract of claim 2.
JP2001267545A 2001-09-04 2001-09-04 Anti-inflammatory plant component Expired - Lifetime JP4864252B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001267545A JP4864252B2 (en) 2001-09-04 2001-09-04 Anti-inflammatory plant component

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001267545A JP4864252B2 (en) 2001-09-04 2001-09-04 Anti-inflammatory plant component

Publications (2)

Publication Number Publication Date
JP2003073315A true JP2003073315A (en) 2003-03-12
JP4864252B2 JP4864252B2 (en) 2012-02-01

Family

ID=19093660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001267545A Expired - Lifetime JP4864252B2 (en) 2001-09-04 2001-09-04 Anti-inflammatory plant component

Country Status (1)

Country Link
JP (1) JP4864252B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004323362A (en) * 2003-04-21 2004-11-18 Musashino Meneki Kenkyusho:Kk Composition comprising extract from plant of genus bidens
JP2004352680A (en) * 2003-05-30 2004-12-16 Musashino Meneki Kenkyusho:Kk Composition for treatment of allergic disease
JP2007112774A (en) * 2005-10-24 2007-05-10 Musashino Meneki Kenkyusho:Kk Cyclo-oxygenase 2 selective inhibitor
JP2009292849A (en) * 2009-09-24 2009-12-17 Musashino Meneki Kenkyusho:Kk Composition containing extract of plant belonging to the genus bidens
CN101884677A (en) * 2010-06-28 2010-11-17 钟弦 Chinese medicinal composition for treating stasis acute appendicitis
CN104666503A (en) * 2015-03-10 2015-06-03 刘占锋 Traditional Chinese medicine composition for treating acute appendicitis
CN104758402A (en) * 2015-03-31 2015-07-08 苏州市天灵中药饮片有限公司 Traditional Chinese medicine decoction for treating chronic appendicitis and preparation method of traditional Chinese medicine decoction
CN105250782A (en) * 2015-11-13 2016-01-20 庄小侃 Pharmaceutical composition for treating chronic appendicitis and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04243834A (en) * 1991-01-09 1992-08-31 Youki Rin Pharmaceutical composition
JP2001178390A (en) * 1999-12-28 2001-07-03 Musashino Meneki Kenkyusho:Kk Method of processing spanish needle
JP2001233727A (en) * 2000-02-22 2001-08-28 Musashino Meneki Kenkyusho:Kk Cosmetic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04243834A (en) * 1991-01-09 1992-08-31 Youki Rin Pharmaceutical composition
JP2001178390A (en) * 1999-12-28 2001-07-03 Musashino Meneki Kenkyusho:Kk Method of processing spanish needle
JP2001233727A (en) * 2000-02-22 2001-08-28 Musashino Meneki Kenkyusho:Kk Cosmetic

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004323362A (en) * 2003-04-21 2004-11-18 Musashino Meneki Kenkyusho:Kk Composition comprising extract from plant of genus bidens
JP4495406B2 (en) * 2003-04-21 2010-07-07 株式会社武蔵野免疫研究所 Sendangusa plant extract-containing composition
JP2004352680A (en) * 2003-05-30 2004-12-16 Musashino Meneki Kenkyusho:Kk Composition for treatment of allergic disease
JP2007112774A (en) * 2005-10-24 2007-05-10 Musashino Meneki Kenkyusho:Kk Cyclo-oxygenase 2 selective inhibitor
JP2009292849A (en) * 2009-09-24 2009-12-17 Musashino Meneki Kenkyusho:Kk Composition containing extract of plant belonging to the genus bidens
CN101884677A (en) * 2010-06-28 2010-11-17 钟弦 Chinese medicinal composition for treating stasis acute appendicitis
CN104666503A (en) * 2015-03-10 2015-06-03 刘占锋 Traditional Chinese medicine composition for treating acute appendicitis
CN104758402A (en) * 2015-03-31 2015-07-08 苏州市天灵中药饮片有限公司 Traditional Chinese medicine decoction for treating chronic appendicitis and preparation method of traditional Chinese medicine decoction
CN105250782A (en) * 2015-11-13 2016-01-20 庄小侃 Pharmaceutical composition for treating chronic appendicitis and application thereof

Also Published As

Publication number Publication date
JP4864252B2 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
AshwlayanVD et al. Therapeutic potential of Calendula officinalis
Wiart Anti-inflammatory plants
Lu et al. Zanthoxylum nitidum (Roxb.) DC: Traditional uses, phytochemistry, pharmacological activities and toxicology
US8597695B1 (en) Herbal combinations for treatment of a skin condition
Arun et al. Phytopharmacological profile of Jasminum grandiflorum Linn.(Oleaceae)
EP3498288A1 (en) Herbal combinations for treatment of a skin condition
Yashaswini et al. Health and nutrition from ornamentals
KR100847439B1 (en) Trachelospermi caulis extracts compositions for treating or preventing inflammatory diseases
Mirzaee et al. Therapeutic activities and phytochemistry of Physalis species based on traditional and modern medicine
Dharani et al. An Illustrated Guide to Medicinal Plants of East Africa
Kumari et al. A holistic overview of different species of Potentilla a medicinally important plant along with their pharmaceutical significance: A review
KR20180130080A (en) Anti-inflammatory composition comprising extracts of grasses and preparing method thereof
JP2003073315A (en) Anti-inflammatory vegetable ingredients
JPH0616530A (en) Cosmetic
Dadhwal et al. Ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological profile of Morus alba L.: a comprehensive review
US20170049835A1 (en) Herbal Combinations For Treating Scalp Conditions
Hurinanthan Anti-HIV activity of selected South African medicinal plants
Kalicharan et al. Ethnopharmacology and biological activities of the Aizoaceae
KR101131719B1 (en) Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases
Bader et al. Medicinal Plants and their Contribution in Socio-Economic Upliftment of the Household in Gurez Valley (J&K)
Eshiet et al. Herbal benefits of tea
Caliskan Medicinal Plants of Turkey
Berköz Nigella sativa L.
Chattopadhyay et al. Preliminary phytochemical screening and in vitro evaluation of anthelmintic activity of leaves and stem bark of Mangifera Indica L.(Anacardiaceae)
KR101093731B1 (en) Liriope platyphylla extracts compositions for treating or preventing inflammatory diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080730

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080730

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110808

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111031

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111109

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141118

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4864252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term